Pages

Friday, February 8, 2013

Indian Institute of Finance Invites Application for Ph.D in Finance Program


Applications are invited by Indian Institute of Finance (IIF), Delhi for admission to three year Doctor of Philosophy (Ph.D) program in Finance for the commencing session 2013.
Eligibility Criteria for IIF, Delhi
  • Candidates holding post graduation in any discipline with minimum of 60% marks (55% marks for SC/ST/OBC) are eligible to apply.
  • Final year candidates may apply.
For more details and information on eligibility criteria, please visit their official website.
How to Apply for IIF, Delhi
  • Candidates must appear for the written test.
  • Candidates must fill up online application from at http://registration.iif.edu  or obtain prospectus & application form on payment of Rs. 1250/- (US $ 50 or Rs. 2500 for overseas) by account payee demand draft drawn in favor of “Indian Institute of Finance” payable at Delhi, from IIF, Ashok Vihar-II, P.O. Box 8486, Delhi-110052 or IIF Publication Division, A-10, Sector 83, Noida, U.P. 201305.
For more details and information on how to apply, please visit their official website.
Selection Procedure for IIF, Delhi
  • IIF uses CAT/XAT/AIMA-MAT/CMAT(AICTE)/GMAT for short listing candidates only. AICTE/IIMs/XLRI/AIMA has no role either in the selection process or in the conduct of the programs.
  • Admission to IIF programs is very rigorous and purely based on merit.
For more details and information on selection procedure, please visit their official website.
Important Dates
Last date of submission of application form: Sunday, March 31, 2013.
For more information on college and courses, please click IIF, Delhi

National Institute of Epidemiology Invites Applications for Master of Public Health Program


Applications are invited by National Institute of Epidemiology (NIE), Chennai for admission to two year Master of Public Health (MPH) program offered in Epidemiology and Health Systems at ICMR School of Public Health for the commencing session 2013.
Eligibility Criteria for National Institute of Epidemiology
  • Candidates holding M.B.B.S degree recognized by Medical Council of India are eligible to apply.
  • Candidates working in public health, preferably in State or Central Government Department or in Medical institutions, sponsored on deputation for two years on full-time basis are eligible to apply.
  • Candidates with three years of experience in public health related activities are eligible to apply.
  • Candidates having age up to 45 years as on 1.7.2013 are eligible to apply.
  • SC/ST/OBCIPH candidates will be eligible for age relaxation as per government of India rules.
How to Apply for National Institute of Epidemiology
  • Candidates can download the Information brochure and prescribed application form from the official website.
  • Applications should be submitted along with the application fee of Rs.600/-(Rupees Six hundred only) by means of a demand draft drawn on any nationalized bank in favor of "SCTIMST" payable at Thiruvananthapuram. Applications without the application fee will not be considered.
For more details and information on how to apply, please visit their official website.
Selection Procedure for National Institute of Epidemiology
Selections of candidates are done based on the following:
  • Review of the application form
  • Written test (if necessary)
  • Personal interview at NIE, Chennai
Important Dates
Last date for receipt of application form: Friday, March 01, 2013.
For more information on college and courses, please click National Institute of Epidemiology, Chennai

JECRC University, Jaipur Invites Applications for M.Tech Program


Applications are invited by JECRC University, Jaipurfor admission to Master of Technology (M.Tech) program offered in various branches for the commencing session 2013.
For more information on various branches, please click here.
Eligibility Criteria for JECRC University
  • B.Tech candidates with minimum of 55% aggregate marks (50% for SC/ST/OBC) in related discipline are eligible to apply.
  • Candidates with MCA/M.Sc.IT may also be considered for M.Tech in Computer Science/Information Technology.
How to Apply for JECRC University
Candidates can apply online by visiting the official website.
For more details and information on how to apply, please visit their official website.
Selection Procedure for JECRC University
  • The selections of candidates will be done based on the marks obtained in B.Tech program.
  • The university may also conduct an entrance test if necessary.
For more details and information on selection procedure, please visit their official website.
Important Dates
Last date for online application: Monday, July 08, 2013.
For more information on college and courses, please click JECRC, Jaipur

Ranchi Institute of Neuro-Psychiatry and Allied Sciences Invites Applications for Medical Programs

Applications are invited by Ranchi Institute of Neuro-Psychiatry and Allied Sciences (RINPAS), Ranchi for admission to Doctor of Philosophy (Ph.D) in Clinical Physiology, Doctor of Philosophy (Ph.D) in Psychiatric Social Work, Master of Philosophy (M.Phil) in Clinical Psychology, Master of Philosophy (M.Phil) in Psychiatric Social Work and Diploma in Psychiatric Nursing for the commencing session 2013.
Eligibility Criteria for RINPAS, Ranchi:
  • For Ph.D. in Clinical Psychology: Candidates holding a diploma / M. Phil in Medical and Social Psychology or Clinical Psychology (2 years) are eligible to apply.
  • For Ph.D. in Psychiatric Social Work: M. A. Social Work or M.S.W. of a recognized university with minimum 60% marks, or DPSW/M.Phil in Psychiatric Social Work.
  • For M.Phil in Clinical Psychology: M.A. in Psychology of a recognized University with minimum 50% marks in the aggregate.
  • For M.Phil in Psychiatric Social Work: M.A. Social Work/Sociology of a recognized university with minimum 50% marks in the aggregate.
  • For Diploma in Psychiatric Nursing: ‘A’ Grade Certificate or Diploma in General Nursing and Midwifery.
How to Apply for RINPAS, Ranchi:
  • Candidates can download the application form from the official website.
  • Completed application form should reach on or before 2nd March 2013 to the Director, Ranchi Institute of Neuro-Psychiatry & Allied Sciences (RINPAS), Kanke, Ranchi – 834006 along with a nonrefundable demand draft of Rs.1000/- (Rs.500/- only in case of ST/SC candidates) drawn in favor of the Director, RINPAS.
For more details and information on how to apply, please visit their official website.
Selection Procedure for RINPAS, Ranchi:
Candidates will be selected based on the written examination conducted by the institute.
Important Dates:
  • Last date for receiving completed applications form: Saturday, March 2, 2013.
  • Date of written examination: Wednesday, March 20, 2013.
For more information on college and courses, please click RINPAS, Ranchi

Sunday, January 27, 2013

Snoring Can Affect The Carotid Artery

People who snore regularly have a much higher risk of having thicker or abnormal carotid arteries, researchers from the Henry Ford Hospital, Detroit, reported. They added that the risk is greater for snorers than overweight people and smokers.

When the lining of the two blood vessels that nourish the brain with oxygen-rich blood thicken, it is usually the first step towards the development of atherosclerosis(hardening of the arteries), the researchers explained. Atherosclerosis causes several vascular diseases.

The left and right common carotid arteries supply the head and neck with oxygenated blood - they divide the neck to form the external and internal carotid arteries.

Lead study author Robert Deeb, M.D., said:

"Snoring is more than a bedtime annoyance and it shouldn't be ignored. Patients need to seek treatment in the same way they would if they had sleep apnea, high blood pressure or other risk factors for cardiovascular disease.

Our study adds to the growing body of evidence suggesting that isolated snoring may not be as benign as first suspected. So instead of kicking your snoring bed partner out of the room or spending sleepless nights elbowing him or her, seek out medical treatment for the snorer."


The researchers found that snorers, including those with no sleep apnea, had alterations in the carotid artery. They believe the changes are most likely caused by trauma and subsequentinflammation that the snoring vibrations cause.

The scientists presented their findings at the 2013 Combined Sections Meeting of the Triological Society in Scottsdale, Arizona. They also submitted their research to The Laryngoscope for publication.

Research findings on snoring have been contradictory

In October 2012, researchers from the Woolcock Institute of Medical Research, Australia, found that snoring is not a risk factor for cardiovascular disease or mortality, regardless of whether or not the person has sleep apnea. They added that those who snore every night are not more likely to die within the next seventeen years than relatively infrequent snorers.

Hungarian researchers in 2008 reported in the journal Sleep that loud snorers are considerably more likely to develop stroke and heart disease compared to those who never or very rarely snore. Their study, involving 12,643 Hungarian adults, found that about 40% of males and 24% of females snore regularly.

Snoring causes cardiovascular disease, long before OSA does

OSA (obstructive sleep apnea) has been linked to the development of cardiovascular disease, as well as some other illnesses.

The scientists believe that for cardiovascular disease, the problem probably starts with snoring, long before OSA sets in. So far, very few studies have demonstrated an association between snoring and cardiovascular disease risk.

Dr. Deeb along with senior study author Kathleen Yaremchuk, M.D. gathered and examined data on 913 patients who had been evaluated by the Henry Ford Hospital's sleep center. The patients had taken part in a diagnostic sleep study from December 2006 to January 2012. They were aged from 18 to 50 years; none of them had sleep apnea at baseline.

Fifty-four of the patients completed the snore outcomes survey which examined their snoring habits. They had also undergone a carotid artery duplex ultrasound to determine how thick the intima-media of their carotid arteries were.

Carotid intima-media thickness is a measurement of the two innermost layers of the arterial wall, and can be used to determine whether there is any atherosclerotic disease. If the intima-media is too thick, it is usually an initial sign of carotid artery disease.
 The researchers found that snorers have considerably thicker intima-media of the carotid arteries compared to people who do not snore.

There was no considerable difference in intima-media thickness between patients with traditional cardiovascular disease risk factors and those without. Risk factors for cardiovascular disease include high blood pressure (hypertension), high blood cholesterol(hypercholesterolemia), smoking and diabetes.

Dr. Deeb said:

"Snoring is generally regarded as a cosmetic issue by health insurance, requiring significant out-of-pocket expenses by patients. We're hoping to change that thinking so patients can get the early treatment they need, before more serious health issues arise."


The team plan to carry out another long term study on people who snore during their sleep. They say they will focus on whether there is a link between cardiovascular event rates and snoring.

The study was funded by the Henry Ford Hospital.

What are the causes of snoring?

Snoring occurs when the soft tissue at the back of a person's head and neck vibrates as they breathe in.

The following tissue may be affected:
  • the nasal passages
  • the soft palate - the soft tissue at the back of the roof of the mouth
  • the base of the tongue
  • the tonsils
  • the uvula - a soft section of tissue that hangs from the soft palate between a person's tonsils
When we sleep, the airways in our head and neck relax and gradually narrow. Experts explain that this airways narrowing raises the speed at which air is breathed in and out, causing changes in pressure inside, making the soft tissue vibrate as the sides of the airways are sucked inwards.

The same can occur when the airways are partially blocked, as may be the case with enlarged tonsils or when somebody has a cold.

Doctors say that snoring typically gets worse over time if it is not treated. The muscles gradually get weaker, making it harder to keep the airways open, resulting in even more frequent and louder snoring.

The following situations, illnesses and conditions are linked to a higher risk of habitual snoring:
  • Being obese - especially if there is a lot of fat around the person's neck.
  • Alcohol - when we drink alcohol our muscles relax
  • Some antidepressants and sedatives - some of these drugs relax the muscles, raising the risk of snoring
  • Tobacco smoking - the airways are more likely to become inflamed, making them narrower, resulting in snoring
  • Allergic rhinitis - when the inside of the nose swells up because of an allergic reaction. Dust or pollen (hay fever) are common examples of allergic rhinitis
Written by Christian Nordqvist
Copyright: Medical News Today 

Three Type 2 Diabetes Pills From Takeda Approved By FDA

Nesina (alogliptin) tablets, Oseni (alogliptin and pioglitazone) tablets, and Kazano (alogliptin and metformin hydrochloride) tablets, for the treatment of type 2 diabetes, for use along with diet and exercise, have been approved by the Food and Drug Administration. They are designed to improve blood sugar control.

The active ingredients pioglitazone and metformin hydrochloride are already approved by the FDA for type 2 diabetesmanagement - Alogliptin is new.

According to the FDA in a communiqué issued on January 25th, 2013, 24 million Americans live with type 2 diabetes, which accounts for over 90% of all diabetes cases in the country.

Patients with type 2 diabetes either do not produce enough insulin, or are resistant to it - in both cases their blood sugar levels are too elevated. Eventually, high blood sugar levels can lead to serious and life-threatening complications, such as kidney damage, blindness and heart disease.

Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research, said:

"Controlling blood sugar levels is very important in the overall treatment and care of diabetes. Alogliptin helps stimulate the release of insulin after a meal, which leads to better blood sugar control."


Nesina, Oseni and Kazano were studied as monotherapies and also in combination with insulin and sulfonylureas. A monotherapy is a stand-alone therapy, one that is not given in combination with another drug.

These therapies should not be prescribed for patients with type 1 diabetes or people with diabetic ketoacidosis (high ketone urine levels).

Nesina (alogliptin) tablets

Nesina is a DPP-4i (dipeptidyl peptidase-4 inhibitor). It is designed to slow down the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide).

Nesina (alogliptin) was shown to be both effective and safe in 14 human studies, which included 8,500 participants; all of them with type 2 diabetes:
  • Patients on Nesina had reductions in HbA1c (glycosylated hemoglobin) of 0.4% to 0.6% compared to those on placebo after 26 weeks on the medication

  • The FDA says it needs five post-marketing Nesina studies: "a cardiovascular outcomes trial; an enhanced pharmacovigilance program to monitor for liver abnormalities, serious cases of pancreatitis, and severe hypersensitivity reactions; and three pediatric studies under the Pediatric Research Equity Act (PREA), including a dose finding study and two safety and efficacy studies, one with Nesina as a monotherapy and one with Nesina and metformin."

  • Nesina's most commonly reported side effects included upper respiratory tract infection,headache, and runny nose.
  • Kazano (alogliptin and metformin hydrochloride) tablets

    Kazano is a combination of alogliptin and metformin HCl, a extensively used anti-diabetes medication, in a single tablet.
  • Kazano was shown to be both safe and effective in four clinical trials, which included over 2,500 participants, all of them with type 2 diabetes:
    • Those on Kazano had additional reductions in HbA1c of 1.1% over Nesina, and 0.5% over metformin after being on therapy for 26 weeks

    • The FDA says it needs two post-marketing Kazano studies: a pediatric efficacy and safety study under PREA, and an enhanced pharmacovigilance program to check for liver abnormalities, pancreatitis, and severe hypersensitivity reactions

    • It carries a Boxed Warning regarding lactic acidosis (accumulation of lactic acid in the bloodstream), which is linked to metformin use

    • The most commonly reported side effects related to Kazano were stuffy/runny nose, sore throat, headache, hypertensiondiarrheaback painurinary tract infection, and upper respiratory tract infection.

    Oseni (alogliptin and pioglitazone) tablets

    Oseni, a combination of alogliptin and pioglitazone, is the first medication in the USA to include both a DPP-4i and a TZD (thiazolidinedione) in a single tablet.

    Oseni was shown to be both safe and effective in four clinical trials which included over 1,500 participants, all of them with type 2 diabetes:
    • The patients on Oseni had additional reductions in HbA1c of 0.4% to 0.6% over pioglitazone alone, and 0.4% to 0.9% over alogliptin alone

    • The FDA says it needs an enhanced pharmacovigilance program for Oseni to check for abnormalities of the liver, pancreatitis, and severe hypersensitivity reactions

    • There is a Boxed Warning in the Oseni packaging, warning about heart failure linked to pioglitazone use

    • The most commonly reported side effects related to Oseni are sore throat, runny nose, upper respiratory infection, and back pain.
    Oseni, Kazano and Nesina are made and distributed by Takeda Pharmaceuticals America, Inc., Deerfield, Illinois, USA.

    Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc., said:

    "Takeda is pleased with the FDA approval of NESINA, OSENI and KAZANO for the treatment of type 2 diabetes, a therapeutic category in which we have more than twenty years of clinical and patient experience. Millions of people are affected by diabetes and, as a leader in the diabetes arena, Takeda is dedicated to working to advance patient care and helping to meet the needs of this growing patient population."


    According to Takeda, type 2 diabetes is a "progressive and chronic (long-term) condition." Patients should work with a doctor to manage and monitor their disease. As well as adhering to a diet and exercise program, patients need to take several drugs in order to help them manage their blood glucose levels.

    Currently, approximately $471.6 billion are spent annually worldwide on diabetes (both types 1 and 2). The International Diabetes Federation estimates that this yearly expenditure will rise to over $595 billion within the next 17 years.

    Written by Joseph Nordqvist 
  • Copyright: Medical News Today 

CBSE launches assessment training programme

KOCHI: Central Board of Secondary Education's Centre for Assessment, Evaluation & Research (CAER) has launched an assessment trainingprogramme. 

CBSE had established CAER through public private partnership with Pearson Foundation. 

The purpose of the Centre is to develop global capabilities and resources for schools, teachers and key functionaries of school management. 

It is envisaged through this endeavour that a symbiosis of the expertise and experience of the board and the partner organization, Pearson Foundation, will help in bringing about an overall improvement in the quality of learning, assessment, research and professional development. 

It is important for all the stakeholders in the CBSE affiliated schools to know that the Centre which has taken strides to formulate the first of a series of professional development programmes for teachers and principals will roll out its Assessment Training Programme (ATP) in February 2013. 

The ATP comprises four modules — constructing quality multiple choice items to assess the scholastic skills of the curriculum, constructing quality constructed-response items to assess the scholastic skills of the curriculum, formative assessment and the use of performance standards for assessing scholastic and co-scholastic skills and classroom-based research. 

"Participation in all four modules and the fulfilment of the required follow up activity will allow those attending to submit evidence for a qualification. Whether or not delegates opt for the qualification, successful participation will create a pool of assessment experts in the country as well as build assessment capacity of teachers in India. All CBSE schools may consider participating whole heartedly in the aforesaid programme", CBSE circular to schools state. 
Source:The Times Of India